Tracks outcomes of people with relapsed myeloma treated with teclistamab or talquetamab
Describes use of teclistamab or talquetamab in adults with relapsed myeloma outside trials.
Plain-language title generated from the registry record
Registry title: A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Key facts
- Where
- Chemnitz, Dresden, Hamburg, Hanover, Heidelberg, Nuremberg, and Würzburg, GermanySee the 7 sites
Where in Germany
- Klinikum Chemnitz gGmbHChemnitz, GermanyNo longer taking part
- Universitätsklinikum Carl Gustav Carus DresdenDresden, GermanyNo longer taking part
- University hospital Hamburg EppendorfHamburg, GermanyTaking people
- Klinikum Region Hannover Klinikum SiloahHanover, GermanyTaking people
- Uniklinikum Heidelberg 1Heidelberg, GermanyNo longer taking part
- Klinikum Nürnberg NordNuremberg, GermanyNo longer taking part
- Universitätsklinikum Würzburg Med. Klinik U. Poliklinik IiWürzburg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Janssen-Cilag Ltd.
- Trial code
- NCT06285318
- Record updated
- 28 August 2026
- Original description
The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.Read full original descriptionShow less
64007957MMY4004: 64007957MMY4004 - REALiTEC
The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.
Inclusion: Have a documented diagnosis of multiple myeloma; Received the first dose of teclistamab on or before 31 December 2022, regardless of the duration of teclistamab treatment (REALiTEC cohort 1) OR Received the first dose of teclistamab from 01 January 2023 to 31 December 2024, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 2) OR Received the first dose of teclistamab from 01 January 2025 to 31 December 2025, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 3) OR Received the first dose of talquetamab on or before 31 December 2023, regardless of the duration of talquetamab treatment (REALiTAL cohort). Participants who received both teclistamab \& talquetamab can be included in both REALiTEC and REALiTAL cohorts; Received at least one dose of teclistamab/talquetamab; Provision of a patient-signed informed consent form (ICF), or an ICF waiver for deceased patients as applicable based on country/site-specific requirements.
Exclusion: To be excluded from REALiTEC cohorts if received teclistamab as part of an interventional clinical trial; To be excluded from REALiTAL cohort if received talquetamab as part of an interventional clinical trial; Participants who have received teclistamab as part of a Janssen pre-approval access program are excluded from the REALiTEC Cohort 2 and REALiTEC Cohort 3.